Boston Scientific (NYSE:BSX) Updates FY 2025 Earnings Guidance

Boston Scientific (NYSE:BSX) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 2.870-2.940 for the period, compared to the consensus earnings per share estimate of 2.880. The company issued revenue guidance of $19.3 billion-$19.6 billion, compared to the consensus revenue estimate of $19.5 billion. Boston Scientific also updated its Q2 2025 guidance to 0.710-0.730 EPS.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on BSX. Citigroup reaffirmed a “buy” rating and issued a $125.00 target price (up from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. BTIG Research reaffirmed a “buy” rating and issued a $124.00 target price on shares of Boston Scientific in a report on Wednesday, April 23rd. Wall Street Zen raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, April 29th. Barclays raised their price objective on shares of Boston Scientific from $118.00 to $125.00 and gave the stock an “overweight” rating in a research note on Friday, April 25th. Finally, Morgan Stanley lifted their price target on shares of Boston Scientific from $120.00 to $125.00 and gave the company an “overweight” rating in a report on Friday, May 16th. Twenty-one analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Boston Scientific currently has an average rating of “Buy” and an average price target of $116.00.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $99.60 on Friday. Boston Scientific has a fifty-two week low of $71.88 and a fifty-two week high of $107.17. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The company has a market cap of $147.35 billion, a PE ratio of 79.68, a P/E/G ratio of 2.79 and a beta of 0.68. The firm has a 50-day simple moving average of $101.03 and a 200 day simple moving average of $98.68.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.08. The company had revenue of $4.66 billion during the quarter, compared to analyst estimates of $4.57 billion. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The business’s revenue for the quarter was up 20.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.56 EPS. On average, sell-side analysts anticipate that Boston Scientific will post 2.85 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, SVP Vance R. Brown sold 4,826 shares of the company’s stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $95.09, for a total value of $458,904.34. Following the transaction, the senior vice president now owns 36,193 shares in the company, valued at approximately $3,441,592.37. This represents a 11.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael F. Mahoney sold 164,443 shares of the company’s stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $102.48, for a total transaction of $16,852,118.64. Following the completion of the transaction, the chief executive officer now owns 1,535,706 shares in the company, valued at approximately $157,379,150.88. This represents a 9.67% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 411,970 shares of company stock worth $42,406,693. 0.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Boston Scientific stock. Brighton Jones LLC boosted its position in Boston Scientific Co. (NYSE:BSX) by 0.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 27,376 shares of the medical equipment provider’s stock after buying an additional 226 shares during the quarter. Brighton Jones LLC’s holdings in Boston Scientific were worth $2,445,000 at the end of the most recent reporting period. Institutional investors own 89.07% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.